BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA ...
An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ...
A BridgeBio Pharma drug developed for an increasingly prevalent cardiovascular condition has won FDA approval, marking a comeback for a company and a molecule with a turbulent history. But BridgeBio’s ...
BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. The Food and Drug ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. BridgeBio’s recently ...
BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby ...
On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce ...
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
Whoever says the Food and Drug Administration is too cozy with Big Pharma isn’t paying attention to the bonanza of new treatments launched by biotech startups. Late last week the FDA approved ...
Near-complete in vitro TTR stabilization was observed as early as day 28 and through completion of a 30-month study of patients with ATTR-CM. The Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results